Drug intelligence / Profile preview

metformin + ethinylestradiol + drospirenone

Development stage: Preclinical
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of metformin (an insulin sensitizer), ethinylestradiol and drospirenone (components of oral contraceptives). This combination is primarily used in the treatment of polycystic ovary syndrome (PCOS), addressing insulin resistance, hormonal imbalance, and associated symptoms like endothelial dysfunction, hyperandrogenism, and metabolic abnormalities.

Brand names: metformin + Yasmin
Other names: metformin + drospirenone/ethinyl estradiol

Targets

PR (Progesterone receptor)ER (Estrogen receptor)INSR (Insulin receptor)AR (Adrenergic receptors)FSHR (Follicle-stimulating hormone receptor)MR (Mineralocorticoid receptor)LHCGR (Luteinizing hormone/choriogonadotropin receptor)

Beyond the preview

Go deeper on metformin + ethinylestradiol + drospirenone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on metformin + ethinylestradiol + drospirenone.

Explore the full profile